AVTX - Company ID 0001534120
The table below shows Avalo Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | - | - | $249.00K | $0.00 |
| Cost of revenue | - | - | $0.00 | - | -$714.00K | $343.00K |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A |
Avalo Therapeutics, Inc. reported annual revenue of $59.00K for fiscal year 2025. That is down 86.6% from $441.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $1.15M (FY 2016) to $59.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.85M |
| $5.58M |
| $5.24M |
| $5.55M |
| $4.29M |
| $4.53M |
| Operating income | -$20.90M | -$19.20M | -$19.32M | -$14.67M | -$12.86M | -$9.57M |
| Income tax | $12.00K | $11.00K | $16.00K | $8.00K | -$14.00K | $7.00K |
| Net income | -$19.63M | -$30.63M | -$20.77M | -$13.15M | $23.04M | $98.46M |
| EPS (diluted) | -$0.98 | -$2.19 | -$1.92 | -$1.25 | -$2.83 | -$14.07 |